MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia

Phase 2
Completed
Conditions
Pneumonia
First Posted Date
2005-11-22
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
604
Registration Number
NCT00257049

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder

Phase 3
Completed
Conditions
Manic Episode
Bipolar Disorders
First Posted Date
2005-11-22
Last Posted Date
2011-01-14
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
267
Registration Number
NCT00257075

A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers

Phase 1
Completed
Conditions
Contraception
Female Contraception
First Posted Date
2005-11-17
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
34
Registration Number
NCT00254865

A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine

Phase 3
Completed
Conditions
Vascular Headaches
Migraine
First Posted Date
2005-11-15
Last Posted Date
2010-04-28
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
211
Registration Number
NCT00253175

A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder

Phase 3
Completed
Conditions
Manic Disorder
Bipolar Disorders
First Posted Date
2005-11-15
Last Posted Date
2011-01-24
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
158
Registration Number
NCT00253149

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Phase 3
Completed
Conditions
Alzheimer Disease
Dementia
First Posted Date
2005-11-15
Last Posted Date
2011-05-23
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
973
Registration Number
NCT00253214
© Copyright 2025. All Rights Reserved by MedPath